JUBILANT PHARMA LIMITED

(Company Registration No. 200506887H) (Incorporated in the Republic of Singapore) Registered office: 80 Robinson Road, #02-00, Singapore 068898

February 28, 2019

Singapore Exchange Securities Trading Limited

11 North Buona Vista Drive #06-07 The Metropolis Tower 2 Singapore 138589

Dear Sirs,

Sub: Issuance of rated unsecured bonds under Regulation S of the U.S. Securities Act of 1933, as amended.

Further to the disclosure made to the stock exchange on February 25, 2019, we wish to inform you that the Company has successfully priced its rated unsecured bonds (the "**Notes**") at 6.00% per annum issued at par for US\$200 million maturing in March, 2024.

S&P Global Ratings ("S&P") has affirmed BB-/positive rating and Fitch Ratings ("Fitch") has affirmed BB-/Stable rating for the Company. The Notes have been rated BB- by S&P and BB by Fitch.

The major portion of the net proceeds of the Notes shall be used to refinance existing indebtedness and pay associated fees and premiums over a period of time and the balance amount for working capital and general corporate purposes.

The above is for your information and records. The Company will provide further updates in this regard, if and when necessary.

We request you to take the same on record.

This notice is not for distribution in or into the United States. This notice is not an offer for sale of any securities in the United States or any jurisdiction. Securities may not be offered or sold in the United States or any jurisdiction absent registration or an exemption from registration under applicable laws and regulations. Any public offering of securities to be made in the United States would be made by means of a prospectus that would contain detailed information about the issuer, their management and their financial statements in compliance with all relevant laws. The issuer does not have any current intention to make any public offering of, or to register, any securities in the United States.

Thanking you,

Yours Faithfully,

For Jubilant Pharma Limited

Arun Kumar Sharma Chief Financial Officer